Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifasutenizol (TNP-2198) Combinations for H. pylori Eradication
NCT06076694Phase 2Completed
- Sponsor
- TenNor Therapeutics
- Start
- Jun 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rifasutenizol in Helicobacter pylori infection (5 arms), sponsored by TenNor Therapeutics. Primary endpoint: The Eradication Rate of Helicobacter Pylori Infection. Started Jun 2022; status: completed.
02
Drugs
rifasutenizol
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT06076694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06076694.